In Hereditary transthyretin amyloidosis OMIM 105210 (TTR, OMIM 105210), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4289, γ 1.3098, spinodal 0.5770). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Hereditary transthyretin amyloidosis OMIM 105210 is an R19 double-well emerged from the real proximal-promoter DNA of TTR. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.3098
barrier
0.4289
spinodal
0.5770
s_on / s_off
1.1445 / -1.1445
fragility
0.80
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4289 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating TTR does NOT relieve the disease branch in a TTR model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual TTR allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (lower s toward OFF branch) independently matches an agent already in clinical use for this disease: TTR-lowering siRNA / antisense (patisiran / vutrisiran; inotersen / eplontersen). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. A subcutaneous small interfering RNA that silences hepatic transthyretin mRNA, lowering circulating wild-type and variant TTR so fewer amyloidogenic monomers are available to misfold and deposit. Direction: decrease / clear the amyloidogenic TTR drive. Engaged node: TTR -- the disease gene's transcript. Allele scope: agnostic -- lowers TTR regardless of the variant, and also covers the wild-type protein. Gene-specific to TTR. Distinct from the stabiliser family (tafamidis): this is the lowering/clear lever. The decrease direction recovers an approved indication spanning the polyneuropathy and cardiomyopathy forms.
✓ This is a rediscovery. Vutrisiran (TTR-silencing siRNA) is approved for hereditary ATTR polyneuropathy and ATTR cardiomyopathy (TTR-lowering); the decrease/clear direction recovered an approved indication. This is the lowering lever, distinct from the tafamidis stabiliser family.
Safety (qualitative; no magnitude). siRNA class; injection-site and reduced-serum-vitamin-A signals on label (vitamin-A supplementation advised); hepatic monitoring (qualitative; no magnitude)
Falsifier. If vutrisiran (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a TTR model, the h-restore(clear) direction is refuted for vutrisiran here.
Source: FDA label: vutrisiran (Amvuttra); Fontana 2025 NEJM 392:33 (HELIOS-B)
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of TTR; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).